{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:00:44Z","timestamp":1794556844963,"version":"4.9.1"},"reference-count":20,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2013,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A number of novel therapies are under investigation in relapsed or refractory peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is unknown. We examined the survival of patients with PTCL after relapse or progression in the absence of hematopoietic stem-cell transplantation and explored factors influencing survival. The three most common subtypes encountered in North America were evaluated: PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL; anaplastic lymphoma kinase [ALK] positive and ALK negative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>After exclusions, 153 patients were analyzed (PTCL-NOS, n = 79 [52%]; AITL, n = 38 [25%]; ALK-positive ALCL, n = 11 [7%]; ALK-negative ALCL, n = 27 [16%; including ALK status unknown, n = 1]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median time from initial diagnosis to relapse or progression after primary therapy was 6.7 months, and median age at relapse was 66 years (ALK-positive ALCL, 39 years). Median overall survival (OS) and median progression-free survival (PFS) after relapse or progression (second PFS) were 5.5 and 3.1 months, respectively, and were only marginally better in patients who received chemotherapy at relapse (n = 89 [58%]; 6.5 and 3.7 months, respectively). Patients with good performance status (PS) of 0 or 1 (n = 47) at relapse who received chemotherapy had a more favorable OS (P &lt; .001; median OS, 13.7 months) and PFS (P = .006; median second PFS, 5.0 months), which remained significant in multivariate analysis (OS: hazard ratio [HR], 2.09; P = .002; second PFS: HR, 1.66; P = .030).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most patients with relapsed or refractory PTCL have poor outcomes with short survival. Select patients with good PS have more favorable outcomes with standard chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2012.44.7524","type":"journal-article","created":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T03:19:22Z","timestamp":1366687162000},"page":"1970-1976","source":"Crossref","is-referenced-by-count":403,"title":["Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors"],"prefix":"10.1200","volume":"31","author":[{"given":"Vivien","family":"Mak","sequence":"first","affiliation":[{"name":"Vivien Mak, Princess Margaret Hospital, Hong Kong, China; Jeremey Hamm, Tamara Shenkier, Richard Klasa, Laurie H. Sehn, Diego Villa, Randy D. Gascoyne, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency, Vancouver; and Mukesh Chhanabhai, Surrey Memorial Hospital, Surrey, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremey","family":"Hamm","sequence":"additional","affiliation":[{"name":"Vivien Mak, Princess Margaret Hospital, Hong Kong, China; Jeremey Hamm, Tamara Shenkier, Richard Klasa, Laurie H. Sehn, Diego Villa, Randy D. Gascoyne, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency, Vancouver; and Mukesh Chhanabhai, Surrey Memorial Hospital, Surrey, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Chhanabhai","sequence":"additional","affiliation":[{"name":"Vivien Mak, Princess Margaret Hospital, Hong Kong, China; Jeremey Hamm, Tamara Shenkier, Richard Klasa, Laurie H. Sehn, Diego Villa, Randy D. Gascoyne, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency, Vancouver; and Mukesh Chhanabhai, Surrey Memorial Hospital, Surrey, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Shenkier","sequence":"additional","affiliation":[{"name":"Vivien Mak, Princess Margaret Hospital, Hong Kong, China; Jeremey Hamm, Tamara Shenkier, Richard Klasa, Laurie H. Sehn, Diego Villa, Randy D. Gascoyne, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency, Vancouver; and Mukesh Chhanabhai, Surrey Memorial Hospital, Surrey, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Klasa","sequence":"additional","affiliation":[{"name":"Vivien Mak, Princess Margaret Hospital, Hong Kong, China; Jeremey Hamm, Tamara Shenkier, Richard Klasa, Laurie H. Sehn, Diego Villa, Randy D. Gascoyne, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency, Vancouver; and Mukesh Chhanabhai, Surrey Memorial Hospital, Surrey, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"Vivien Mak, Princess Margaret Hospital, Hong Kong, China; Jeremey Hamm, Tamara Shenkier, Richard Klasa, Laurie H. Sehn, Diego Villa, Randy D. Gascoyne, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency, Vancouver; and Mukesh Chhanabhai, Surrey Memorial Hospital, Surrey, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"Vivien Mak, Princess Margaret Hospital, Hong Kong, China; Jeremey Hamm, Tamara Shenkier, Richard Klasa, Laurie H. Sehn, Diego Villa, Randy D. Gascoyne, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency, Vancouver; and Mukesh Chhanabhai, Surrey Memorial Hospital, Surrey, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"Vivien Mak, Princess Margaret Hospital, Hong Kong, China; Jeremey Hamm, Tamara Shenkier, Richard Klasa, Laurie H. Sehn, Diego Villa, Randy D. Gascoyne, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency, Vancouver; and Mukesh Chhanabhai, Surrey Memorial Hospital, Surrey, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Vivien Mak, Princess Margaret Hospital, Hong Kong, China; Jeremey Hamm, Tamara Shenkier, Richard Klasa, Laurie H. Sehn, Diego Villa, Randy D. Gascoyne, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency, Vancouver; and Mukesh Chhanabhai, Surrey Memorial Hospital, Surrey, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"Vivien Mak, Princess Margaret Hospital, Hong Kong, China; Jeremey Hamm, Tamara Shenkier, Richard Klasa, Laurie H. Sehn, Diego Villa, Randy D. Gascoyne, Joseph M. Connors, and Kerry J. Savage, British Columbia Cancer Agency, Vancouver; and Mukesh Chhanabhai, Surrey Memorial Hospital, Surrey, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","first-page":"4124","volume":"46","author":"Vose J","year":"2008","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2916"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"B4","first-page":"116","author":"Sibon D","year":"2010","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"B8","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (ed 4)","author":"Swerdlow SH","year":"2008"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20587"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh409"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"B13","author":"Reimer P","journal-title":"Adv Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162401"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3264"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.515"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8470"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"B19","first-page":"118","author":"Coiffier B","year":"2011","journal-title":"Blood"},{"key":"B20","first-page":"118","author":"Forero-Torres A","year":"2011","journal-title":"Blood"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2012.44.7524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T19:18:18Z","timestamp":1653506298000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2012.44.7524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,1]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2013,6,1]]}},"alternative-id":["10.1200\/JCO.2012.44.7524"],"URL":"https:\/\/doi.org\/10.1200\/jco.2012.44.7524","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718002433.793475987","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,1]]}}}